These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2453339)

  • 1. [Antipsychotic efficacy of neuroleptic neuropeptides in schizophrenia. Review of clinical data].
    Verhoeven VM
    Encephale; 1987; 13(6):349-56. PubMed ID: 2453339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Endogenous opioids and gamma type endorphins in schizophrenia].
    Verhoeven WM
    Arch Neurobiol (Madr); 1983; 46(5):335-8. PubMed ID: 6362599
    [No Abstract]   [Full Text] [Related]  

  • 3. Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients.
    Emrich HM; Zaudig M; Kissling W; Dirlich G; von Zerssen D; Herz A
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Sep; 13(5):290-8. PubMed ID: 7003611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of schizophrenic psychoses with gamma-type endorphins.
    van Praag HM; Verhoeven WM; van Ree JM; de Wied D
    Biol Psychiatry; 1982 Jan; 17(1):83-98. PubMed ID: 6174158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Endorphins and schizophrenias. II. Trial treatment of schizophrenia with des-Tyr-gamma-endorphin (DT gamma E) (including a personal trial)].
    Bourgeois M; Laforge E; Muyard J; Blayac J; Lemoine J
    Ann Med Psychol (Paris); 1980 Nov; 138(9):1112-9. PubMed ID: 6111283
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical, biochemical, and hormonal aspects of treatment with Des-tyr1-gamma-endorphin in schizophrenia.
    Verhoeven WM; van Ree JM; Westenberg HG; Krul JM; Brouwer GJ; Thijssen JH; de Wied D; van Praag HM; Ceulemans DL; Kahn RS
    Psychiatry Res; 1984 Apr; 11(4):329-46. PubMed ID: 6204351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-opiate effects of neuropeptides derived from beta-endorphin.
    De Wied D; Van Ree JM
    Pol J Pharmacol Pharm; 1987; 39(5):623-32. PubMed ID: 2976164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic-like and antipsychotic effects of gamma-type endorphins.
    Van Ree JM; Verhoeven WM; Van Praag HM; De Wied D
    Mod Probl Pharmacopsychiatry; 1981; 17():266-78. PubMed ID: 6173744
    [No Abstract]   [Full Text] [Related]  

  • 9. Antipsychotic action of gamma-type endorphins: animal and human studies.
    van Ree JM; Verhoeven WM; Claas FH; de Wied D
    Prog Brain Res; 1986; 65():221-35. PubMed ID: 2431435
    [No Abstract]   [Full Text] [Related]  

  • 10. Gamma-type endorphins: neurolepticum-like and antipsychotic action.
    Van Ree JM; Verhoeven WM; De Wied D
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):561-7. PubMed ID: 2418467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Benzamides, a therapeutic response adapted to 2 sides, paranoid and hebephrenic, of schizophrenia].
    Cassan P
    Ann Med Psychol (Paris); 1985 Jul; 143(7):677-82. PubMed ID: 2870674
    [No Abstract]   [Full Text] [Related]  

  • 12. [Endorphins of the gamma type in the treatment of schizophrenic psychoses].
    Verhoeven WM; Van Ree JM
    Acta Psychiatr Belg; 1984; 84(2):160-72. PubMed ID: 6204507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (Des-tyrosine1)-gamma-endorphin in schizophrenia: clinical, biochemical, and hormonal aspects.
    Verhoeven WM; Westenberg HG; Gerritsen TW; van Praag HM; Thijssen JH; Schwarz F; van Ree JM; de Wied D
    Psychiatry Res; 1981 Dec; 5(3):293-309. PubMed ID: 7034028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study on the antipsychotic properties of desenkephalin-gamma-endorphin and ceruletide in schizophrenic patients.
    Verhoeven WM; Westenberg HG; van Ree JM
    Acta Psychiatr Scand; 1986 Apr; 73(4):372-82. PubMed ID: 3524119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of schizophrenic psychoses with gamma-type endorphins].
    van Praag HM; Verhoeven WM; van Ree JM; de Wied D
    Ned Tijdschr Geneeskd; 1981 Nov; 125(48):1963-9. PubMed ID: 6171738
    [No Abstract]   [Full Text] [Related]  

  • 17. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.
    Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ
    Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127
    [No Abstract]   [Full Text] [Related]  

  • 18. A long-term pilot study of pipothiazine palmitate in chronic schizophrenia.
    Villeneuve A; Pires A; Jus A; Lachance R; Drolet A
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):696-706. PubMed ID: 4404626
    [No Abstract]   [Full Text] [Related]  

  • 19. Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?
    Corves C; Engel RR; Davis J; Leucht S
    Acta Psychiatr Scand; 2014 Jul; 130(1):40-5. PubMed ID: 24299424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness of treating early-onset malignant schizophrenia with psychotropic drugs and their combinations].
    Sobolev ES; Zaĭtsev SG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(1):114-21. PubMed ID: 6111878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.